Abvc Biopharma (ABVC) Accumulated Depreciation (2010 - 2026)

Abvc Biopharma (ABVC) has 8 years of Accumulated Depreciation data on file, last reported at $3.4 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 1.08% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 1.08% YoY) and the FY2025 annual result came in at $3.4 million, up 1.15% from the prior year.
• Accumulated Depreciation steadied at $3.4 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $3.4 million in Q2 2025 to a low of $3.3 million in Q4 2022.
• A 5-year average of $3.4 million and a median of $3.3 million in 2025 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2024 — Accumulated Depreciation gained 0.2% — and 2025, when it grew 1.83%.
• Tracing ABVC's Accumulated Depreciation over 5 years: stood at $3.3 million in 2022, then grew by 0.93% to $3.3 million in 2023, then rose by 0.2% to $3.3 million in 2024, then advanced by 1.15% to $3.4 million in 2025, then rose by 0.02% to $3.4 million in 2026.
• The last three Accumulated Depreciation figures came in at $3.4 million (Q1 2026), $3.4 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.